Cuprina Holdings To Acquire East Coast Podiatry And Orchard Clinic For ~$3.1M

Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)Target Group generated FY2025 unaudited revenue of approximately S$9.1 million and unaudited normalized EBITDA of approximately S$1.2 million, based on unaudited management accountsSellers’ consideration shares subject to a lock-upAdds an established clinical platform directly aligned with Cuprina’s wound-care and collagen technologiesSINGAPORE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or the "Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it has entered into Sale and Purchase Agreements (the "SPAs") to acquire the entire issued and paid-up share capital of (i) East Coast Podiatry Centre Pte. Ltd. ("ECPC"), which operates East Coast Podiatry Clinic ("ECP"), the leading podiatry-focused chain in Singapore; and (ii) Orchard Clinic Management Pte. Ltd. ("OCM"), which operates Orchard Clinic ("ORC"), a Singapore women’s health and wellness clinic (ECPC and OCM together, the "Target Group"), through its direct wholly-owned subsidiary, Cuprina Holdings (BVI) Limited.Under the SPAs, an aggregate purchase consideration of approximately S$4.0 million (approximately US$3.1 million) will be satisfied as follows (i) S$3.0 million (equivalent to approximately 75% of the consideration) in cash, comprising approximately S$0.5 million paid upon execution, S$1.35 million payable upon closing, and S$1.15 million in deferred cash consideration payable over a two-year period; and (ii) S$1.0 million1 (equivalent to approximately 25% of the consideration) in Class A ordinary shares of the Company (the "Consideration Shares"). The consideration shares will be subject to lock-up as set forth in the SPAs and ancillary documents. Completion is subject to customary closing conditions and is expected to occur on or before November 1, 2026. Following completion, the Company expects to consolidate the financial results of the Target Group.